1. Stem Cell Therapy

Category Archives: Stem Cell Therapy

Stem cell therapy could reverse Type 2 diabetes, UBC study finds

Posted on by

VANCOUVER -- University of B.C. scientists appear to be one step closer to reversing diabetes using stem cell therapy.

The latest study, published last week in the journal Stem Cell Reports, found that Type 2 diabetes can be eliminated in mice using a combination of conventional diabetes drugs and specially cultured stem cells. Similar methods have already been used to reverse Type 1 diabetes, which usually begins in childhood.

The team simulated Type 2 diabetes in mice by feeding them a high-fat, high-calorie diet for several weeks. In humans, Type 2 usually begins in adulthood and can be a result of obesity, poor diet and lack of exercise.

Like diabetic humans, the diabetic mice treated only with drugs experienced spikes in their blood sugar levels after eating sugary meals.

But the mice that were surgically implanted with pancreatic-like cells grown from human stem cells didnt have those drastic swings and were able to regulate their blood sugar like healthy animals.

Being able to reduce spikes in blood sugar levels is important because evidence suggests its those spikes that do a lot of the damage increasing risks for blindness, heart attack, and kidney failure, said Timothy Kieffer, a professor in UBCs department of cellular and physiological sciences.

So far, the researchers have followed the mice for up to seven months, and theyve remained healthy.

When we removed the transplanted devices and analyzed the cells within, they still appear very healthy so we believe they will function much longer. Ultimately the duration of cell function will need to be assessed in humans, Kieffer said in an email.

Human trials are already underway for stem cell therapy on Type 1 diabetes; the first patient was implanted with cells in October.

The treatment also had a surprising side-effect: weight loss. The mice all returned to the same, healthy weight as the animals in the control group.

Read the original post:

Stem cell therapy could reverse Type 2 diabetes, UBC study finds

Nevada Pain Now Offering Stem Cell Therapy to Help Patients Delay or Avoid Joint Replacement

Posted on by

Las Vegas, Nevada (PRWEB) March 23, 2015

Nevada Pain, the top pain management clinics in Las Vegas and Henderson areas, are now offering stem cell therapy to help patients delay or avoid the need for joint replacement. The treatments are cutting edge, outpatient, and highly effective. Call (702) 323-0553 for more information and scheduling.

Stem cell therapy for joint arthritis has rapidly become mainstream due to its effectiveness for pain relief. Unlike traditional treatments, the regenerative medicine therapies actually have the potential to change the course of arthritis rather than simply provide a proverbial "band aid" to the condition.

The stem cell treatments are provided by Board Certified, Fellowship Trained pain doctors who have extensive experience with the procedures into all extremity joints including the hip, knee, shoulder and ankle. There are multiple types of stem cell treatments. Some involve amniotic fluid derived treatment, which contains an immense amount of stem cells, growth factors, hyaluronic acid and anti-inflammatory mediators as well.

Bone marrow derived treatment is also available, which also contains an immense amount of stem cells and growth factors. The treatments are provided as an outpatient, and often provide pain relief and functional improvement.

Platelet Rich Plasma Therapy is also offered, which involves a simple blood draw. The platelets are then concentrated and immediately injected into the problem area.

For more information and scheduling with the top regenerative medicine clinic in Las Vegas, call (702) 323-0553.

The rest is here:

Nevada Pain Now Offering Stem Cell Therapy to Help Patients Delay or Avoid Joint Replacement

Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for …

Posted on by

BANGALORE, March 23, 2015 /PRNewswire/ --

- The First Stem Cell Drug Based on Pooling Technology to be Granted ATMP Classification

- A New Treatment Which Offers Hope to Patients Suffering From Thromboangiitis Obliterans (Buerger's Disease) Affecting an Estimated 2 out of Every 10,000 People in Europe

- The First Real Hope for Patients Facing Limb Amputation

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO). The ATMP classification, approved by the committee for Advanced Therapies (CAT) of the European Medicines Agency, will allow Stempeutics to commercialize the product 'Stempeucel' across the European Union region.

(Logo: http://photos.prnewswire.com/prnh/20150323/735846 )

Thromboangiitis Obliterans is a recurring progressive inflammation and thrombosis (clotting) of small and medium arteries and veins of the feet. It is strongly associated with use of tobacco products primarily from smoking, but also from smokeless tobacco. Stempeucel drug is expected to address the root cause of the disease through anti-inflammatory and immune-modulatory mechanisms. It is expected to induce angiogenesis through release of vascular endothelial growth factors, epithelial growth factors, angiopoietin and improve the perfusion and help the repair and regeneration of the ischemic muscle tissue.

The aim of the ATMP classification is to regulate cell and gene therapy and tissue engineered medicinal products, providing a benchmark for a level of quality compliance for pharmaceutical practices. The regulation provides guidelines to research development companies for following a standardized process in order to obtain approval in EU countries. The regulation also offers incentives to companies involved in developing ATMPs in the European Union, including fee reductions for scientific advice, scientific recommendations on ATMP classification and evaluation and certification of quality and non-clinical data.

Commenting on the ATMP classification, Mr B N Manohar, CEO of Stempeutics said, "We are happy to receive ATMP status from the EMA. We view this as an important milestone to further develop our novel stem cell biological drug Stempeucel in the EU for treating Thromboangiitis Obliterans indication. Additionally, we interpret this as a favourable indication for how the European regulators view our therapy."

Dr. Jeff Karp, Associate Professor of Medicine, Harvard Medical School, who serves as Scientific Advisor to Stempeutics said, "I see Stempeutics as a global regenerative medicine company that could make a significant difference to disease treatment. Stempeutics has an impressive combination of exciting technologies and it has been wonderful to work with the team as they achieve critical milestones and advance their products to patients."

Continue reading here:

Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for ...

Stem Cell Therapy, Stem Cell Treatments, Stem Cell Clinics …

Posted on by

With the onset of Alzheimers disease, information transfer at the synapses (the connection between the nerve cells and extensions) starts to break down, and the number of synapses decreases significantly.

Autoimmune diseases are conditions in which the patients immune system generates cellular and antibody responses to substances and tissues normally present in the body.

In each condition there is chronic obstruction of the flow of air through the airways and out of the lungs, and the obstruction generally is permanent and may be progressive over time.

Diabetes is the condition in which the body does not properly process food for use as energy. When you have diabetes, your body either doesn't make enough insulin or can't use its own insulin as well as it should.

Multiple sclerosis (or MS) is a degenerative disease involving the deterioration of nerve cells. MS attacks the central nervous system (CNS), which is made up of the brain, spinal cord, and optic nerves.

Osteoarthritis, or degenerative joint disease, is the most common type of arthritis. It is caused by the degradation of a joints cartilage.

Parkinson's disease is a chronic progressive neurological disease that affects nerve cells (neurons) in an area of the brain known as the substantia nigra.

Rheumatoid Arthritis is an autoimmune disease that attacks the bodys own tissues, specifically the synovium, a thin membrane lining the joints. As a result, joint fluid builds up, causing pain in the joints and inflammation thats systemic.

Read the original post:

Stem Cell Therapy, Stem Cell Treatments, Stem Cell Clinics ...

Stem cell therapy may help treat type 2 diabetes

Posted on by

A human embryonic stem cell line derived at Stanford University.(REUTERS/Julie Baker/Stanford University School of Medicine/California Institute for Regenerative Medicine/Handout)

Type 2 diabetes is marked by insulin resistance, or the bodys inability to store sugar and convert it into carbohydrates for energy. Overcoming that resistance is the main hurdle scientists face in creating new treatment for the condition, but researchers in Canada have found a promising means for doing so: combining stem cell therapy and antidiabetic medication.

Type 2 diabetes accounts for nearly 95 percent of the 400 million diabetes cases worldwide. Current treatment often involves imprecise insulin injection, and can produce side effects like unwanted weight gain, gastrointestinal issues and low blood glucose levels. Eighty percent of Type 2 diabetes patients are overweight.

In the study, published Thursday in the journal Stem Cell Reports, scientists observed that transplanting pancreatic stem cells derived from human cells into mice with Type 2 diabetes symptoms, then administering common antidiabetic drugs, improved the mices glucose metabolism, body weight and insulin sensitivity three hallmark problems associated with the condition.

There have been similar reports looking at treatment of type 1 diabetes by stem cell-based replacement, and there are many people around the world who are interested in that, lead study author Timothy J. Kieffer, a molecular and cellular medicine professor at the University of British Columbia, in Vancouver, told FoxNews.com. Until this point, nobody to our knowledge had tested such a stem cell-based transplant study in a Type 2 diabetes model.

Many people have predicted this approach to fail because one of the characteristics of Type 2 diabetes is insulin resistance and so it was generally thought that simply replacing insulin wouldn't be effective, Kieffer added.

Researchers fed four separate groups of immunosuppressed mice a different diet to try to emulate humans diagnosed with Type 2 diabetes. One group of mice received a 45 percent fat diet; one a 60 percent fat diet; one a high-fat, Western diet; and the last a low-fat diet. No single group of mice developed a phenotype that exactly mimicked a Type 2 diabetes human patient, but all three high-fat groups ended up exhibiting characteristics that mirrored the hallmark features of the condition.

Study authors transplanted human embryonic stem cell (hESC)-derived pancreatic progenitor cells into the mice after they began exhibiting symptoms. These cells are programmed to expand and differentiate when transplanted and to subsequently secrete insulin.

To transplant the human cells, researchers used a macroencapsulation device, a mechanism that is meant to prevent the body from detecting nonnative material as foreign and subsequently rejecting it. Because the mice were immunosuppressed, the device wasnt necessary, but Kieffer said his team used it so their findings would be more relevant for future clinical trials, wherein the patients would not be immunosuppressed. Researchers opted to induce Type 2 diabetes symptoms in immunosuppressed mice with diet instead of using a mouse model genetically engineered to assume Type 2 diabetes for that same reason.

The hope in the field is that some sort of device will eliminate the need for immunosuppression when cells are transplanted, Kieffer said.

Read the original here:

Stem cell therapy may help treat type 2 diabetes

Welcome To Atlanta Stem Cell Treatment – Atlanta Stem Cell …

Posted on by

Aesthetic Body Sculpture Clinic Center of Anti-Aging is now offering several treatment packages for Anti-Aging and Life Extension including Adult Stem Cell Therapy. The Goal with all treatment packages is always to offer a better Quality of Life during the Aging Process, by optimizing the body from the inside out. Adult Stem Cell Treatment, PRP (Platelet Rich Plasma) Treatment& Bio-Identical Hormone Replacement Therapy as a combination treatment package can assist in regaining youthful energy, better sleep quality, increased sexual function, not to mention it may limit aches and pains that often come with the aging process or from sustained injuries along the way. Adult Stem Cell Therapy has also been known to reduce the symptoms of Osteoarthritis and COPD. Though we cannot guarantee results or make any claims, there seems to be a direct connection in patients receiving treatment experiencing an increase in vitality and a decrease in chronic pain and fatigue.

Beautiful Uniquely Different People DESERVE Individualized Treatments

Dr. Monte Slater believes that by designing individualizing programs for Anti-Aging & Life Extension along with setting realistic expectations, that everyone should experience a positive change in their day to day lives. One of the big concerns among middle aged active adults is the limitations that can be experienced when it comes to sports such as tennis, squash, golf and similar activities. Dr. Slater is a double board certified physician with a passion for Anti-Aging and Longevity. Within recent years he became very interested in Adult Stem Cell Therapy and the positive effects on the aging body. Already board certified in Anti-Aging & Regenerative Medicine, it made sense to incorporate Adult Stem Cell Therapy as an aid for a better quality life while aging. As a Military Officer and board certified OBGYN, he had to work with womens health issues daily. It was the foundation for what was yet to come. The journey has now taken him and his team to Atlanta Georgia, where he is able to offer superior medical service to folks interested in living healthier longer lives.

Osteoarthritis is a very painful condition of the joints which often limits mobility. Usually seen in older individuals but not entirely uncommon in younger patients, osteoarthritis can lead to malformed joints, an inability to perform or enjoy everyday tasks and even disability. How Stem Cells can Help Autologous Adipose-derived Stem Cells (ASCs) are a novel therapy for patients with Osteoarthritis.

Atlanta Stem Cell Treatment Center offers effective Anti-Aging Treatment with Adult stem cells. Anti-Aging Therapy can assist in improving overall physical health of the patients life, resulting in less tiredness, better sleep quality, improvement in vitality and overall quality of life.

Excerpt from:

Welcome To Atlanta Stem Cell Treatment - Atlanta Stem Cell ...

Study Shows Liposuction Byproduct Could Lead to ED Cure

Posted on by

Durham, NC (PRWEB) March 19, 2015

A new study appearing in STEM CELLS Translational Medicine has moved science one step closer to finding a simple treatment for erectile dysfunction (ED) after prostate cancer surgery, eschewing the usual pharmaceutical drug route with potential for harmful side effects, in favor of stem cell therapy that can help the body regenerate.

The study, conducted in rats, compares the effectiveness of using a byproduct of liposuction uncultured stromal vascular fraction (SVF) with adipose-derived stem cells (ADSCs) cultured in the lab to treat ED caused by injury to the cavernous nerve (CN). This nerve, which facilities erection, is sometimes injured during a radical prostatectomy to treat prostate cancer.

ADSCs are harvested from fat and are an attractive source of stem cells for several reasons: They are abundant and can be easily obtained using minimally invasive liposuction. Also, they have characteristics similar to bone marrow-derived stem cells in terms of self-renewal and multipotency. Furthermore, ADSCs retain their ability to divide and grow longer than bone marrow-derived stem cells, which may be beneficial in treating chronic conditions.

On the other hand, cultured ADSCs have limitations, including the cost and time of culturing them, the potential for contamination, changes in cell characteristics during culturing procedures, and their tendency to sometimes form tumors. To avoid these risks, uncultured SVF has emerged as an easier and safer way to use stem and progenitor cells (which are further along in the differentiation process) derived from adipose tissue. SVF comes from the disposable byproduct of liposuction.

However, no study had yet reported side-by-side comparisons of uncultured SVF and cultured ADSCs in treating ED. That was the objective of this study, led by Dalsan You, M.D., Ph.D., and Choung-Soo Kim, M.D., Ph.D., and their colleagues at the Asan Medical Center and University of Ulsan College of Medicine in Seoul, Korea. They tested the cells using 40 rats with and without injured CNs. One group of animals was injected with cultured ADSCs; one received uncultured SVF, and a control group received no stem cells. Four weeks later, both sources of stem cells had significantly improved the animals erection function over the control group. Also, both stem cell types significantly increased the number of nNOS-positive nerve fibers, suggesting that they stimulated nerve regeneration.

However, Dr. Kim said, the cells coming from uncultured SVF outperformed the cultured ADSCs in terms of smooth muscle/collagen ratio and endothelial cell content in the blood vessels, which are also important factors in repairing ED.

Further research is now ongoing to determine the optimal protocol for cellular therapy of ED following CN injury, Dr. You added. We want to follow the progress of the animals over the long term and also we want to see what happens with multiple stem cell injections, rather than just the one given in this study.

This first study to compare two types of cells derived from fat tissue in a rat model of erectile dysfunction after prostate cancer surgery is an important step in identifying effective new treatments for this condition, said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

###

Follow this link:

Study Shows Liposuction Byproduct Could Lead to ED Cure

Stem cells show promise for reversing type 2 diabetes

Posted on by

IMAGE:This is an image of macro-encapsulated pancreatic endocrine cells derived from human embryonic stem cells. Devices were harvested at 29 weeks post-transplant and immunofluorescent staining was performed for insulin... view more

Scientists at the University of British Columbia and BetaLogics, part of Janssen Research & Development, LLC have shown for the first time that Type 2 diabetes can be effectively treated with a combination of specially-cultured stem cells and conventional diabetes drugs.

Stem cells - generic cells that haven't yet taken on specialized form and function - have recently been used by scientists at UBC and elsewhere to reverse Type 1 diabetes in mice. In Type 1 diabetes, which usually begins in childhood, the pancreas produces little or no insulin, the hormone that enables cells to metabolize sugar.

These new results, published today in Stem Cell Reports, hold much broader potential because Type 2 diabetes - which usually arises in adulthood, often stemming from poor diet, lack of exercise and obesity - accounts for more than 90 per cent of diabetes cases.

Timothy Kieffer, a professor in the department of cellular and physiological sciences, and scientists from BetaLogics simulated Type 2 diabetes in mice by putting them on a high-fat, high-calorie diet for several weeks. Kieffer's team then surgically implanted pancreatic-like cells that had been grown in the laboratory from human stem cells.

Mice that received a combination of the cells with one of three diabetes drugs became as "glucose tolerant" as the healthy mice, meaning they were able to keep their blood sugar in check, even after ingesting a sugary meal. In contrast, a group of mice with simulated Type 2 diabetes that received the drugs but not the transplants remained glucose-intolerant.

"Being able to reduce spikes in blood sugar levels is important because evidence suggests it's those spikes that do a lot of the damage - increasing risks for blindness, heart attack, and kidney failure," says Kieffer, a member of UBC's Life Sciences Institute.

The combination therapy also produced an unexpected, but welcome result: the mice returned to a normal weight, the same weight as a healthy control group that had been reared on a low-fat diet.

"Their weight loss was intriguing, because some of the common diabetes therapies often lead to weight gain," Kieffer said. "We need to do more studies to understand how the cell transplants lead to weight loss."

The team is also investigating if higher doses of the cells - beyond the five million tested in this study - can achieve the same results without the need for additional drugs.

See more here:

Stem cells show promise for reversing type 2 diabetes

Arthritis of low back, knees, and shoulder 2 years after stem cell therapy by Harry Adelson ND – Video

Posted on by


Arthritis of low back, knees, and shoulder 2 years after stem cell therapy by Harry Adelson ND
Jim describes his results two years after bone marrow stem cell therapy by Harry Adelson ND for treatment of his arthritic low back, knees, and shoulder http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read more here:

Arthritis of low back, knees, and shoulder 2 years after stem cell therapy by Harry Adelson ND - Video

BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York

Posted on by

HACKENSACK, N.J.and PETACH TIKVAH, Israel, March 18, 2015 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 in New York City.

Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialization, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.

The following are specific details regarding BrainStorm's presentation:

Event:

ARM's Regen Med Investor Day

Date:

March 25, 2015

Time:

4:20 PM EST

Location:

View original post here:

BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York

UM stem cell research on heart may go national

Posted on by

Written by Lidia Dinkova on March 18, 2015

University of Miami stem cell research on generating healthy heart tissue in heart attack survivors is on track to be tested across the US.

The National Heart, Lung and Blood Institute, part of federal medical research arm the National Institutes of Health, is to fund the $8 million cost if the trial wins necessary approvals.

The trial, the first of this research in humans, is a step toward restoring full heart function in heart attack survivors.

The research developed at the UM Miller School of Medicines Interdisciplinary Stem Cell Institute is on combining two types of stem cells to generate healthy heart tissue in heart attack survivors. Scientists have in the past studied using one type of stem cell at a time, a method thats worked OK, said Dr. Joshua Hare, founding director of the UM stem cell institute.

But UM research shows that combining two types of stem cells expedites healing and regeneration of healthy heart muscle.

We could remove twice the scar tissue than with either cell alone, Dr. Hare said. We had some scientific information that they actually interacted and worked together, so we tested that. It worked.

Researchers combined mesenchymal stem cells, usually generated from human bone marrow, and cardiac stem cells, isolated from a mammals heart.

Stem cells are cells that havent matured to specialize to work in a particular part of the body, such as the heart. Because these cells are in a way nascent, they have the potential to become specialized for a particular body function.

Doctors have been using stem cells to regenerate lost tissue from bones to heart muscle. The mesenchymal and cardiac stem cells each work well in generating healthy heart tissue in heart attack survivors, Dr. Hare said. Combining them expedites the process, according to the UM research.

Link:

UM stem cell research on heart may go national

Dr. Nathan Newman – Stem Cell Therapy and Regenerative Medicine – Video

Posted on by


Dr. Nathan Newman - Stem Cell Therapy and Regenerative Medicine
Dr. Nathan Newman is a Board Certified Dermatologist, a Cosmetic Surgeon, and a pioneer in stem cell therapy and Regenerative Medicine. He is world-renowned for his ground-breaking Stem Cell...

By: 110Seconds

Read the rest here:

Dr. Nathan Newman - Stem Cell Therapy and Regenerative Medicine - Video


  1. Stem Cell Therapy